<DOC>
	<DOC>NCT02247401</DOC>
	<brief_summary>This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment naive and treatment experienced HCV GT4 subjects without or with compensated cirrhosis.</brief_summary>
	<brief_title>Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic hepatitis C, genotype 4infection (HCV RNA level greater than 1,000 IU/mL at Screening) Subjects must meet one of the following: Treatmentnaive: Subject has never received antiviral treatment for hepatitis C infection OR Treatment Experienced (Prior null responders, Partial responders or Relapsers to pegIFN/RBV); Females must be postmenopausal, of nonchild bearing potential or practicing specific forms of birth control In substudy 1, demonstrated absence of liver cirrhosis as confirmed by liver biopsy or Fibroscan In substudy 2, evidence of liver cirrhosis as confirmed by liver biopsy or Fibroscan with ChildPugh score less than or equal to 6 at Screening and confirmed absence of hepatocellular carcinoma Females who are pregnant or breastfeeding Positive screen for hepatitis B Surface antigen or antiHuman Immunodeficiency virus antibody HCV genotype performed during screening indicating unable to genotype or coinfection with any other HCV genotype abnormal laboratory tests selfreports current drinking more than 2 drinks per day current enrollment in another investigational study previous treatment with a direct acting antiviral agent (DAA) containing regimen In substudy 1, evidence of liver cirrhosis In substudy 2, evidence of current or past ChildPugh B or C classification and confirmed presence of hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-responder</keyword>
	<keyword>Egypt</keyword>
	<keyword>HCV</keyword>
	<keyword>null responder</keyword>
	<keyword>Genotype 4</keyword>
	<keyword>compensated cirrhosis</keyword>
	<keyword>naive</keyword>
	<keyword>treatment experienced</keyword>
	<keyword>hepatitis c</keyword>
	<keyword>relapser</keyword>
	<keyword>hepatitis infection</keyword>
	<keyword>partial responder</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>